This site uses cookies to bring you the best experience. Find out more
Skip to main content

News

Find Out The Latest

You can keep in touch with exciting developments for The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also keep up to date by following us on Twitter or LinkedIn    


TOSP agrees to sale of development site to Lawrence J. Ellison Institute for Transformative Medicine

The Oxford Science Park agrees to sale of development site to the Lawrence J. Ellison Institute for Transformative Medicine US research organisation creates new campus to build collaborations across the Oxford life science ecosystem Oxford, UK, July 18 2022 – Leading US-based research organisation, the Lawrence J. Ellison Institute for Transformative Medicine, is significantly expanding its commitment to Oxford by establishing a major presence... Read more

MIROBIO RAISES $97M SERIES B TO DEVELOP CHECKPOINT AGONISTS FOR AUTOIMMUNE DISEASES

MIROBIO RAISES $97 MILLION SERIES B FINANCING TO DEVELOP CHECKPOINT AGONISTS FOR TREATMENT OF AUTOIMMUNE DISEASES Financing led by Medicxi with significant participation from new and existing shareholders Lead program MB272 targeting checkpoint receptor BTLA, entering Phase I clinical trials Funds will be used to advance pipeline of immune checkpoint agonists into clinical trials in autoimmune diseases OXFORD, United Kingdom, June 29... Read more

OMass Therapeutics Wins The Oxford Science Park Innovation Award at Oxfordshire Business Awards

Oxford, United Kingdom – 20 June 2022 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems, is pleased to announce that it has won the Oxford Science Park Innovation Award at the Oxfordshire Business Awards. The Oxfordshire Business Awards recognise, reward and promote the excellence of Oxfordshire-based companies. OMass Therapeutics received the Oxford... Read more

Drug discovery company OMass Therapeutics is 2022 winner of TOSP's Innovation Award

Work to discover drugs for rare and immunological diseases recognised as part of Oxfordshire Business Awards Oxford, UK, June 18 2022 – Its work in discovering medicines for rare and immunological diseases has earned OMass Therapeutics The Oxford Science Park Innovation Award 2022. Given as part of the Oxfordshire Business Awards, it recognises the company’s progress in generating a pipeline of small molecule therapeutics, discovered using... Read more

OxSonics strengthens management team with hire of Dr Marianna Lalla as Chief Medical Officer

OxSonics strengthens management team with appointment of Dr Marianna Lalla as Chief Medical Officer Underpins Company’s strategy to expand its pipeline of clinical combination studies Oxford, UK – 6th June 2022 – OxSonics Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, is pleased to announce that Dr Marianna Lalla has joined the Company as Chief Medical Officer (CMO).... Read more